Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Boehringer, F-star Enter Antibody Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Boehringer, F-star Enter Antibody Pact

Boehringer Ingelheim and F-star, an antibody engineering company based in Vienna, Austria, have entered a collaboration and license agreement for the discovery of new antibody-derived therapeutic products using F-star’s Modular Antibody Technology.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim and F-star, an antibody engineering company based in Vienna, Austria, have entered a collaboration and license agreement for the discovery of new antibody-derived therapeutic products using F-star’s Modular Antibody Technology. Boehringer will select as many as seven targets, which may include multiple therapeutic areas, against which the two companies will work to discover Fcabs for further development and commercialization by Boehringer, either as therapeutic products or as modules for the generation of bispecific mAb2 products.

F-star will receive an initial technology access fee, research-based funding, and is eligible to receive additional license fees, development, regulatory and commercial milestones, as well as royalties on product sales. Boehringer can select several therapeutic products from each of the seven discovery programs. The total payments to F-star for each of these programs, excluding royalty payments, could reach as much as $246 million if commercial success of multiple therapeutic products is acheived.

Dr. Kevin FitzGerald, chief executive officer of F-star, said, “We are very pleased to have completed this agreement with Boehringer Ingelheim and are very excited by the prospect of jointly delivering novel therapeutic proteins to patients with poorly treated illnesses. This partnership will enable F-star to expand the exploitation of its antibody technology by combining with the impressive global research and development capabilities and resources of Boehringer Ingelheim.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters